Search results for "Ovulation"

showing 10 items of 127 documents

Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

2012

Abstract OBJECTIVE: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS). DESIGN: Cohort. SETTING: Academic practice. PATIENT(S): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects. INTERVENTION(S): Blood and ovarian ultrasound at baseline and after 5 years. MAJOR OUTCOME MEASURE(S): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound. RESULT(S): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyAgingSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectSettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesPCOS AMH Fertility Ovarian function Ovulation Aging HyperandrogenismPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studyOvulationmedia_commonUltrasonographyAntimullerian Hormonebusiness.industryOvaryObstetrics and GynecologyMiddle AgedPolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEndocrinologyReproductive MedicinePredictive value of testsCohortAndrogensFemaleInsulin ResistancebusinessBody mass indexBiomarkersGonadotropinsCohort studyAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct

Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.

2005

CONTEXT: We undertook this study to estimate the prevalence of the various androgen excess disorders using the new criteria suggested for the diagnosis of polycystic ovary syndrome (PCOS). SETTING: The study was performed at two endocrine departments at the University of Palermo (Palermo, Italy). PATIENTS: The records of all patients referred between 1980 and 2004 for evaluation of clinical hyperandrogenism were reevaluated. All past diagnoses were reviewed using the actual diagnostic criteria. To be included in this study, the records of the patients had to present the following available data: clinical evaluation of hyperandrogenism, body weight and height, testosterone (T), free T, dehyd…

AdultHirsutismAdolescent17-alpha-HydroxyprogesteroneBody WeightOvaryAlopeciaBody HeightBody Mass IndexPelvisDiagnosis DifferentialPolycystic ovary syndrome HyperandrogenismNeoplasmsAcne VulgarisAndrogensHumansFemaleTestosteroneHyperandrogenismProgesteroneAnovulationPolycystic Ovary SyndromeRetrospective StudiesUltrasonography
researchProduct

High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms

2010

Objective To verify the conclusions of the Endocrine Society Guidelines that patients with mild hirsutism and no other important clinical signs (menstrual irregularities, infertility, central obesity, acanthosis nigricans, rapid progression of the hirsutism, clitoromegaly) should not be further studied. Design Retrospective study in patients referred because of mild hirsutism and no other clinical signs. Setting Department of Clinical Medicine of the University of Palermo. Patient(s) One hundred fifty-two patients with mild hirsutism. Intervention(s) Measurement of serum testosterone, dehydroepiandrosterone sulfate, 17-OH-Progesterone, assessment of ovulation by measurement of progesterone …

AdultInfertilityHirsutismmedicine.medical_specialtyPediatricsSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectClitoromegalyYoung Adultchemistry.chemical_compoundDehydroepiandrosterone sulfatePrevalenceHumansMedicineOvulationAcanthosis nigricanshirsutismRetrospective Studiesmedia_commonGynecologybusiness.industry17-alpha-HydroxyprogesteroneHyperandrogenismObstetrics and Gynecologymedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsReproductive Medicinechemistrypolycystic ovary syndromeFemalemedicine.symptombusiness
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome

2010

Objective To determine whether luteal phase endometrial transcriptome is altered in obese women during the window of implantation (WOI), considering the presence of infertility, fat distribution and association with polycystic ovary syndrome (PCOS). Design Prospective study. Setting University-affiliated infertility clinic, between May 2007 and March 2009. Patient(s) One control group of women with normal weight (n = 4), and four study groups of obese women (n = 6 each one) according to the association with infertility, PCOS, and ovarian stimulation. Intervention(s) The endometrium was biopsied 7 days after LH surge or hCG administration in 28 women. Main Outcome Measure(s) Endometrial gene…

AdultInfertilitymedicine.medical_specialtyTime FactorsAdolescentMicroarrayBiopsyLuteal PhaseLuteal phasePeptide receptor activityBiologyEndometriumEndometriumYoung AdultOvulation InductionInternal medicinemedicineCluster AnalysisHumansEmbryo ImplantationObesityProspective StudiesOligonucleotide Array Sequence AnalysisUnexplained infertilityPrincipal Component AnalysisGene Expression ProfilingObstetrics and GynecologyFertility Agents Femalemedicine.diseasePolycystic ovarymedicine.anatomical_structureEndocrinologyGene Expression RegulationReproductive MedicineSpainCase-Control StudiesFemaleTransmembrane transporter activityInfertility FemalePolycystic Ovary SyndromeFertility and Sterility
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct

Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome.

2009

Central fat distribution is increased in anovulatory women with polycystic ovary syndrome (PCOS) compared with ovulatory PCOS and matched controls. Among secreted adipocytokines, this is reflected mainly in lower levels of adiponectin.

AdultLeptinOvulationmedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectAdipokineAdipose tissueBiologyAnovulationInsulin resistanceAdipokinesInternal medicinemedicineBody Fat DistributionHumansNicotinamide PhosphoribosyltransferaseOvulationmedia_commonAdiponectinLeptinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryfat distribution; polycystic ovary syndromeLipidsfemale genital diseases and pregnancy complicationsEndocrinologyC-Reactive ProteinPhenotypeReproductive Medicinefat distributionCase-Control StudiesFemaleAdiponectinInsulin ResistanceWaist CircumferenceRetinol-Binding Proteins PlasmaAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Correlates of increased lean muscle mass in women with polycystic ovary syndrome.

2009

ObjectiveMuscle mass plays an important role in determining cardiovascular and metabolic risks in polycystic ovary syndrome (PCOS). In addition, whether lean mass influences carotid intima-media thickness (IMT) in PCOS has not been assessed.DesignProspective investigation.MethodsNinety-five women with PCOS were age- and weight-matched to 90 ovulatory controls. All women had dual X-ray absorptiometry for lean, fat and bone mass, and bone mass density (BMD). Serum testosterone, sex hormone-binding globulin, insulin, and glucose and carotid IMT were determined. Free androgen index (FAI) and insulin resistance (by QUICKI) were calculated.ResultsIn PCOS, waist circumference and insulin were high…

AdultMaleOvulationmedicine.medical_specialtySettore MED/09 - Medicina InternaBone densityAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBiologySettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyWaist–hip ratioInsulin resistanceAbsorptiometry PhotonInternal medicinemedicineHumansInsulinTestosteroneMuscle SkeletalUltrasonographyPCOS Muscle mass Cardiovascular risk atherosclerosis endotheliumFree androgen indexWaist-Hip RatioInsulinBody Weightnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarePolycystic ovaryEndocrinologyCarotid ArteriesLean body massAndrogensBody CompositionFemaleSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieBody mass indexPolycystic Ovary SyndromeEuropean journal of endocrinology
researchProduct

A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilizatio…

2009

Objective To compare the efficacy of three different gonadotropin regimens in an oocyte donation program. The analysis of cost minimization also was evaluated. Design Prospective, randomized, controlled study. Setting Instituto Universitario–IVI, Valencia, Spain. Patient(s) One thousand twenty-eight donors undergoing a GnRH agonist protocol were assigned randomly to one of three groups: group 1 (n = 346), only recombinant FSH (rFSH); group 2 (n = 333), only highly purified menotropin (HP-hMG); and group 3 (n = 349), rFSH plus HP-hMG. One thousand seventy-nine oocyte recipients. Intervention(s) Controlled ovarian stimulation. Main Outcome Measure(s) Controlled ovarian stimulation parameters,…

AdultMaleendocrine systemmedicine.medical_specialtyAdolescentPregnancy Ratemedicine.drug_classmedicine.medical_treatmentFertilization in Vitrolaw.inventionYoung AdultFollicle-stimulating hormoneOvulation InductionRandomized controlled trialCost SavingsPregnancylawmedicineHumansGynecologyIn vitro fertilisationOocyte Donationbusiness.industryOvaryObstetrics and GynecologyFertility Agents FemaleMiddle AgedPregnancy rateTreatment OutcomeReproductive MedicineFemaleOvulation inductionMenotropinGonadotropinbusinessInfertility FemaleGonadotropinsEmbryo qualityFertility and Sterility
researchProduct